API
< Back to all clusters
[HEALTH] · South Korea · 4 sources

started · updated

Dong-A ST launches epilepsy treatment Xcopri in South Korea

Dong-A ST has officially launched Xcopri (cenobamate) in South Korea, a third-generation epilepsy treatment developed by SK Biopharm. The drug is indicated as an adjunctive therapy for adult patients with partial seizures that are not adequately controlled by existing anti-epileptic drugs.

Clinical trials, including Study 017 and an Asian Phase 3 study (Study 035), demonstrated that cenobamate can reduce seizure frequency and achieve seizure freedom. In the Asian study involving patients from South Korea, China, and Japan, the 400mg dose group showed a 52.4 percent seizure freedom rate over a six-week maintenance period.

The medication operates through a dual mechanism: inhibiting persistent sodium currents and enhancing the action of the inhibitory neurotransmitter GABA. Xcopri is covered by national health insurance in South Korea, which is expected to reduce the economic burden on the estimated 360,000 epilepsy patients in the country and improve access to treatment.

Entities

Dong-A ST · SK Biopharm · South Korea · U.S. Food and Drug Administration · Xcopri